GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (STU:TQB) » Definitions » Valuation Rank

ImmunoPrecise Antibodies (STU:TQB) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is ImmunoPrecise Antibodies Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

ImmunoPrecise Antibodies Valuation Rank Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (STU:TQB) » Definitions » Valuation Rank
Comparable Companies
LPCN IBO EDSA ORGS BIVI PTN NNVC CLDI UBX NEUP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IPA:USA TQB:Germany
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
Website
https://www.ipatherapeutics.com
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.